PURE Bioscience to Begin Development of FDA Compliant Operation for Production of Pharmaceutical Grade Silver Dihydrogen Citrate.

SAN DIEGO -- PURE Bioscience (OTCBB:PURE) today announced that it will begin conversion of part of its existing manufacturing space to a dedicated FDA compliant current Good Manufacturing Practices (cGMP) facility for the production of pharmaceutical grade silver dihydrogen citrate.

Michael L. Krall, President and CEO of PURE Bioscience, stated, "As we move forward with testing and regulatory work on silver dihydrogen citrate for use in prescription and personal care products, we are required to produce silver dihydrogen citrate raw material in compliance with the FDA's Good Manufacturing Practices. Fortunately, the space required to produce silver dihydrogen citrate concentrate is small, so design and construction costs are economical."

Krall continued, "To ensure the integrity of the project, we have engaged former PURE Director, Dr. Eugene Peiser, President of Peiser & Associates, Inc., one of the nation's most respected FDA Regulatory Compliance consulting firms, to guide us through this project. Dr. Peiser will make certain that our plant and processes are in compliance with FDA rules and regulations."

PURE Bioscience's flagship technology is a patented, aqueous antimicrobial called silver dihydrogen citrate (SDC). SDC is an electrolytically generated source of stabilized ionic silver that can serve as the basis for a broad range of products in diverse markets. Colorless, odorless, tasteless and non-caustic, SDC formulates well with other compounds. PURE produces and markets pre-formulated, ready-to-use product, as well as varying strengths of SDC concentrate as an additive or raw material for inclusion in other companies' products.

PURE's silver dihydrogen citrate technology shows promise as a broad-spectrum antimicrobial for use in human and veterinary healthcare products. PURE has chosen to pursue approvals through the U.S. Food and Drug Administration (FDA) by partnering with Therapeutics, Incorporated, which has assumed responsibility for funding and managing the testing and regulatory process for potential FDA regulated silver dihydrogen citrate-based products. Therapeutics, Incorporated is focusing on development of silver dihydrogen citrate-based products for the treatment of bacterial, viral and fungal mediated diseases and conditions, beginning with women's health products and acne treatment products. Therapeutics, Incorporated expects its development work will result in multiple Investigational New Drug (IND) filings with the US FDA.

PURE currently has U.S. Environmental Protection Agency (EPA) registration for its 2400-parts per million (ppm) technical grade SDC concentrate (trade name Axenohl(R)) as well as for its Axen(R) and Axen(R)30 hard surface disinfectant products.

Axen30 is distinguished from many of the leading commercial and consumer products because of its superior efficacy combined with its lower toxicity ratings. For example, leading brand household spray disinfectants declare a 10-minute disinfection time against three widespread disease-causing bacteria: Staph, Pseudomonas and Salmonella (Staphylococcus aureus ATCC 6538, Pseudomonas aeruginosa ATCC 15442 and Salmonella choleraesuis ATCC 10708), whereas Axen30 claims a 30-second disinfection time on these same organisms - 20 times faster than the claims made by the leading competitor. Additional claims for Axen30 include a remarkable 24 hour residual kill on standard indicator bacteria, 2 minute kill time on some resistant strains of bacteria, 10 minute kill time on fungi, 30 second kill time on HIV Type I, and 10 minute kill time on other viruses.

Based on the EPA toxicity categorization of antimicrobial products ranging from Category I (high toxicity) down to Category IV, Axen30 is a Category IV antimicrobial for which precautionary labeling statements are normally not required. This compares with Category II warning statements for most leading brands of antimicrobial products.

About PURE Bioscience

PURE Bioscience (PURE) develops and markets technology-based products in the bioscience and water treatment sectors to provide non-toxic solutions to global health challenges. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate antimicrobials and Triglycylboride(TM) pesticides, represent innovative advances in diverse markets. PURE is currently America's leader in pharmaceutical water purification with its Fillmaster(R) equipment, and the Company has expanded into residential water treatment with its Nutripure(R) water filtration systems. PURE Bioscience is headquartered in El Cajon, California (San Diego metropolitan area) and its common stock is listed on the OTC Bulletin Board under the symbol "PURE." Incorporated in 1992, PURE Bioscience was formerly named Innovative Medical Services.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.